Torrent Pharmaceuticals signed a non-exclusive patent licensing agreement with Takeda to bring vonoprazan to the Indian market. Vonoprazan, a cutting-edge potassium-competitive acid blocker (P-CAB), is used to treat gastroesophageal reflux disease (GERD) and other acid-related disorders.
Torrent will market vonoprazan under the brand name kabvie. According to AWACS MAT data from April 2024, the Indian market for GERD treatments is valued at ₹8,064 crore and has been growing at a compound annual growth rate (CAGR) of 8% over the past four years.
As reported by ZEEBUSINESS, treatments like pantoprazole, a proton pump inhibitor (PPI), are commonly used to manage GERD. The introduction of P-CABs like Kabvie will introduce new and effective options for GERD treatment.
